e-CFR Navigation Aids


Simple Search

Advanced Search

 — Boolean

 — Proximity


Search History

Search Tips


Latest Updates

User Info


Agency List

Incorporation By Reference

eCFR logo

Related Resources

Electronic Code of Federal Regulations

We invite you to try out our new beta eCFR site at https://ecfr.federalregister.gov. We have made big changes to make the eCFR easier to use. Be sure to leave feedback using the Feedback button on the bottom right of each page!

e-CFR data is current as of December 2, 2020

Title 21Chapter IIPart 1308 → Subject Group

Title 21: Food and Drugs

Excluded Nonnarcotic Substances

§1308.21   Application for exclusion of a nonnarcotic substance.

(a) Any person seeking to have any nonnarcotic drug that may, under the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 301), be lawfully sold over the counter without a prescription, excluded from any schedule, pursuant to section 201(g)(1) of the Act (21 U.S.C. 811(g)(1)), may apply to the Drug and Chemical Evaluation Section, Diversion Control Division, Drug Enforcement Administration. See the Table of DEA Mailing Addresses in §1321.01 of this chapter for the current mailing address.

(b) An application for an exclusion under this section shall contain the following information:

(1) The name and address of the applicant;

(2) The name of the substance for which exclusion is sought; and

(3) The complete quantitative composition of the substance.

(c) Within a reasonable period of time after the receipt of an application for an exclusion under this section, the Administrator shall notify the applicant of his acceptance or nonacceptance of his application, and if not accepted, the reason therefore. The Administrator need not accept an application for filing if any of the requirements prescribed in paragraph (b) of this section is lacking or is not set forth as to be readily understood. If the applicant desires, he may amend the application to meet the requirements of paragraph (b) of this section. If the application is accepted for filing, the Administrator shall issue and publish in the Federal Register his order on the application, which shall include a reference to the legal authority under which the order is issued and the findings of fact and conclusions of law upon which the order is based. This order shall specify the date on which it shall take effect. The Administrator shall permit any interested person to file written comments on or objections to the order within 60 days of the date of publication of his order in the Federal Register. If any such comments or objections raise significant issues regarding any finding of fact or conclusion of law upon which the order is based, the Administrator shall immediately suspend the effectiveness of the order until he may reconsider the application in light of the comments and objections filed. Thereafter, the Administrator shall reinstate, revoke, or amend his original order as he determines appropriate.

(d) The Administrator may at any time revoke any exclusion granted pursuant to section 201(g) of the Act (21 U.S.C. 811(g)) by following the procedures set forth in paragraph (c) of this section for handling an application for an exclusion which has been accepted for filing.

[38 FR 8254, Mar. 30, 1973, as amended at 70 FR 74657, Dec. 16, 2005; 75 FR 10678, Mar. 9, 2010; 81 FR 97021, Dec. 30, 2016]

§1308.22   Excluded substances.

The following nonnarcotic substances which may, under the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 301), be lawfully sold over the counter without a prescription, are excluded from all schedules pursuant to section 201(g) (1) of the Act (21 U.S.C. 811(g) (1)):

Excluded Nonnarcotic Products

Company Trade name NDC code Form Controlled substance (mg or mg/ml)
Aphena Pharma Solutions—New York, LLCNasal Decongestant Inhaler/Vapor InhalerINLevmetamfetamine (l-Desoxyephedrine)50.00
Bioline LaboratoriesTheophed00719-1945TBPhenobarbital8.00
Goldline LaboratoriesGuiaphed Elixir00182-1377ELPhenobarbital4.00
Goldline LaboratoriesTedrigen Tablets00182-0134TBPhenobarbital8.00
Hawthorne Products IncChoate's Leg FreezeLQChloral hydrate246.67
Parke-Davis & CoTedral00071-0230TBPhenobarbital8.00
Parke-Davis & CoTedral Elixir00071-0242EXPhenobarbital40.00
Parke-Davis & CoTedral S.A.00071-0231TBPhenobarbital8.00
Parke-Davis & CoTedral Suspension00071-0237SUPhenobarbital80.00
Parmed PharmacyAsma-Ese00349-2018TBPhenobarbital8.10
Procter & Gamble Co., TheVicks VapoInhaler37000-686-01INLevmetamfetamine (l-Desoxyephedrine)50.00
Rondex LabsAzma-Aids00367-3153TBPhenobarbital8.00
Smith Kline ConsumerBenzedrex49692-0928INPropylhexedrine250.00
Sterling Drug, IncBronkolixir00057-1004ELPhenobarbital0.80
Sterling Drug, IncBronkotabs00057-1005TBPhenobarbital8.00
White Hall LabsPrimatene (P-tablets)00573-2940TBPhenobarbital8.00

[38 FR 8255, Mar. 30, 1973. Redesignated at 38 FR 26609, Sept. 24, 1973, and amended at 41 FR 16553, Apr. 20, 1976; 41 FR 53477, Dec. 7, 1976; 46 FR 51603, Oct. 21, 1981; 47 FR 45867, Oct. 14, 1982; 54 FR 2100, Jan. 19, 1989; 55 FR 12162, Mar. 30, 1990; 62 FR 13968, Mar. 24, 1997; 74 FR 44283, Aug. 28, 2009; 80 FR 65634, 65637, Oct. 27, 2015; 81 FR 6453, Feb. 8, 2016]

Need assistance?